Previous studies using murine Abs yielded human-anti-mouse-antibody (HAMA) responses, but chimeric Abs are not immunogenic.  Iodine-131 radiolabelled mAbs for the TAA G250 have been studied in a phase I clinical study.  The intent of a phase I study is to test toxicity, and in the phase I study most patients experience mild nausea without vomiting.

    Some data from a phase I study (5):

           patient #5 one week after first injection                             3 weeks after first injection
            Ant.                                    Post.                                Ant.                                    Post.

Steffens et al.: Phase I Radioimmunotherapy of Metastatic Renal Cell Carcinoma with 131-I labelled Chimeric Monoclonal Antibody G250.  Clinical Cancer Research, 5: 3268-3274, 1999.
                   Ant.                                        Post.
           The above pictures are radioimmunoscintigrams of one the patients in the study.  In the left picture, an arrow points to a brain metasteses which was not detected on a subsequent CT scan.
The pictures to the left are of another patient (#2).  Arrows point to 2 bone metastases, a lymph node metastasis, and massive tumor infiltration of the lung.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Below is a table summarizing the results of the study:
 

Steffens et al.: Phase I Radioimmunotherapy of Metastatic Renal Cell Carcinoma with 131-I labelled Chimeric Monoclonal Antibody G250.  Clinical Cancer Research, 5: 3268-3274, 1999.